Display options
Cite
Bolstad I, Andreassen OA, Groote IR, et al. No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol. Front Hum Neurosci. 2015;9:296doi: 10.3389/fnhum.2015.00296.
Bolstad, I., Andreassen, O. A., Groote, I. R., Haatveit, B., Server, A., & Jensen, J. (2015). No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol. Frontiers in human neuroscience, 9296. https://doi.org/10.3389/fnhum.2015.00296
Bolstad, Ingeborg, et al. "No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol." Frontiers in human neuroscience vol. 9 (2015): 296. doi: https://doi.org/10.3389/fnhum.2015.00296
Bolstad I, Andreassen OA, Groote IR, Haatveit B, Server A, Jensen J. No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol. Front Hum Neurosci. 2015 May 26;9:296. doi: 10.3389/fnhum.2015.00296. eCollection 2015. PMID: 26074803; PMCID: PMC4443021.
Copy Download .nbib Format: NLM
Share it on

Front Hum Neurosci. 2015 May 26;9:296. doi: 10.3389/fnhum.2015.00296. eCollection 2015.

No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol.

Frontiers in human neuroscience

Ingeborg Bolstad, Ole A Andreassen, Inge R Groote, Beathe Haatveit, Andres Server, Jimmy Jensen

Affiliations

  1. NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital Oslo, Norway ; Institute of Clinical Medicine, University of Oslo Oslo, Norway.
  2. Department of Psychology, Institute of Social Sciences, University of Oslo Oslo, Norway.
  3. Department of Neuroradiology, Oslo University Hospital Oslo, Norway.
  4. NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital Oslo, Norway ; Centre for Psychology, Kristianstad University Kristianstad, Sweden.

PMID: 26074803 PMCID: PMC4443021 DOI: 10.3389/fnhum.2015.00296

Abstract

BACKGROUND: Aripiprazole is an atypical antipsychotic drug that is characterized by partial dopamine D2 receptor agonism. Its pharmacodynamic profile is proposed to be beneficial in the treatment of cognitive impairment, which is prevalent in psychotic disorders. This study compared brain activation characteristics produced by aripiprazole with that of haloperidol, a typical D2 receptor antagonist, during a task targeting executive functioning.

METHODS: Healthy participants received an acute oral dose of haloperidol, aripiprazole or placebo before performing an executive functioning task while blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) was carried out.

RESULTS: There was a tendency towards reduced performance in the aripiprazole group compared to the two other groups. The image analysis yielded a strong task-related BOLD-fMRI response within each group. An uncorrected between-group analysis showed that aripiprazole challenge resulted in stronger activation in the frontal and temporal gyri and the putamen compared with haloperidol challenge, but after correcting for multiple testing there was no significant group difference.

CONCLUSION: No significant group differences between aripiprazole and haloperidol in frontal cortical activation were obtained when corrected for multiple comparisons. This study is registered in ClinicalTrials.gov (identifier: 2009-016222-14).

Keywords: aripiprazole; dopamine; executive function; fMRI; haloperidol; healthy volunteers

References

  1. Hum Brain Mapp. 2013 Feb;34(2):272-82 - PubMed
  2. J Clin Psychopharmacol. 2012 Dec;32(6):778-86 - PubMed
  3. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6186-91 - PubMed
  4. Schizophr Res. 2013 Oct;150(1):42-50 - PubMed
  5. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6917-22 - PubMed
  6. Psychopharmacology (Berl). 2013 May;227(2):221-9 - PubMed
  7. Eur Neuropsychopharmacol. 2014 Apr;24(4):575-84 - PubMed
  8. J Psychopharmacol. 2012 Jun;26(6):806-12 - PubMed
  9. Neuropsychopharmacology. 2003 Aug;28(8):1400-11 - PubMed
  10. Am J Psychiatry. 1996 Mar;153(3):321-30 - PubMed
  11. Schizophr Res. 2006 Jul;85(1-3):222-31 - PubMed
  12. Appl Neuropsychol. 2009;16(1):62-75 - PubMed
  13. Eur Neuropsychopharmacol. 2012 Jun;22(6):387-400 - PubMed
  14. Neuroimage. 1992 Aug;1(1):43-53 - PubMed
  15. Schizophr Res. 2001 Mar 1;48(1):17-28 - PubMed
  16. Trends Neurosci. 1997 Jan;20(1):31-7 - PubMed
  17. Biol Psychiatry. 2004 May 15;55(10):1013-22 - PubMed
  18. J Neural Transm (Vienna). 2002 Mar;109(3):411-20 - PubMed
  19. Schizophr Res. 2016 Jun;173(3):174-81 - PubMed
  20. Schizophr Res. 2003 Apr 1;60(2-3):285-98 - PubMed
  21. Eur J Clin Pharmacol. 2014 Feb;70(2):127-34 - PubMed
  22. J Clin Psychopharmacol. 2007 Feb;27(1):15-21 - PubMed
  23. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9 - PubMed
  24. Arch Gen Psychiatry. 2009 Jan;66(1):13-20 - PubMed
  25. Nat Neurosci. 2002 Mar;5(3):267-71 - PubMed
  26. Science. 1975 Jun 20;188(4194):1217-9 - PubMed
  27. Schizophr Bull. 2009 May;35(3):549-62 - PubMed
  28. Brain Res. 2009 Aug 25;1286:123-32 - PubMed
  29. Am J Psychiatry. 2009 Jun;166(6):675-82 - PubMed
  30. Nord J Psychiatry. 2014 Apr;68(3):219-24 - PubMed
  31. Acta Psychiatr Scand. 2014 Jul;130(1):1-15 - PubMed
  32. Schizophr Res. 2014 Sep;158(1-3):156-62 - PubMed
  33. Schizophr Res. 2010 May;118(1-3):189-200 - PubMed
  34. J Clin Psychopharmacol. 1999 Jun;19(3):209-21 - PubMed
  35. Psychopharmacology (Berl). 2009 Nov;207(1):35-45 - PubMed
  36. J Psychopharmacol. 2013 Apr;27(4):374-85 - PubMed
  37. Arch Gen Psychiatry. 2012 Aug;69(8):776-86 - PubMed
  38. Philos Trans R Soc Lond B Biol Sci. 1982 Jun 25;298(1089):199-209 - PubMed
  39. Neural Regen Res. 2013 Jan 25;8(3):277-86 - PubMed
  40. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):161-8 - PubMed
  41. Curr Med Res Opin. 2014 Aug;30(8):1629-41 - PubMed
  42. Neuroimage. 2006 May 1;30(4):1332-9 - PubMed

Publication Types